Irbesartan/Hidroclorotiazida Mylan

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan/Hidroclorotiazida Mylan, is an angiotensin II receptor blocker and thiazide diuretic presented as a tablet for oral use. It is prescribed to lower elevated blood pressure in adult patients. GNH USA supplies Irbesartan/Hidroclorotiazida Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is indicated for the management of hypertension, acting on the renin‑angiotensin system and renal sodium handling.

Hypertension: reduces systolic and diastolic blood pressure and lowers cardiovascular risk. Essential hypertension: provides combined vasodilation and diuretic effect for better control. Hypertension with fluid retention: adds diuretic action to counteract volume overload.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Headache or mild fatigue. - Increased urination or nocturia. - Electrolyte changes such as low potassium or sodium. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance requiring medical attention. - Acute kidney injury or worsening renal function. - Significant drop in blood pressure (hypotension). - Allergic reactions including rash, itching, or swelling. - Hyperkalemia when combined with potassium‑sparing agents.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Renal function: check serum creatinine and eGFR periodically. - Electrolytes: monitor potassium and sodium levels, especially in patients on other diuretics. - Diabetes: watch for changes in blood glucose control. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines that affect blood pressure, renal function, or electrolyte balance.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal impairment. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Lithium: may raise lithium levels and cause toxicity. - ACE inhibitors: additive effect on potassium and renal function. - NSAIDs: can blunt antihypertensive effect and impair renal perfusion.

Moderate Interactions (Monitor Closely): - Other antihypertensives: may cause additive hypotension. - Antidiabetic agents: blood glucose may improve, requiring dose adjustment. - CYP3A4 inhibitors (e.g., ketoconazole): may increase irbesartan levels. - Loop diuretics: monitor volume status and electrolytes. - Antacids containing aluminum or magnesium: may reduce absorption of hydrochlorothiazide.